Mesoblast Provides Upcoming Milestones for Remestemcel-L & Quarterly Updates

  • Jul 30, 2020 AEST
  • Team Kalkine

Mesoblast Limited (ASX:MSB) updated on upcoming milestones for its lead product candidate remestemcel-L, along with the activity report for the 4th quarter ended 30 June 2020.

Phase 3 Trial of Remestemcel-L for COVID-19 ARDS is anticipated to complete its recruitment in September 2020 in the US.

The ODAC (Oncologic Drugs Advisory Committee) of the US FDA has scheduled a meeting on 13 August 2020 to review data supporting MSB’s Biologics License Application for approval of RYONCIL in the treatment of SR-aGVHD in children.

Mesoblast disclosed that the company has cash on hand of US$129.3 million at the end of the quarter. Moreover, MSB completed a capital raising of ~US$90 million from global institutional investors in May 2020.


The website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. All pictures are copyright to their respective owner(s). does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK